Comparing Ultrafractionated and Moderate Hypofractionated Radiotherapy for Post-Surgery Breast Cancer
NCT07928427, Phase 3, Active not recruiting, Fudan University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Comparing Ultrafractionated and Moderate Hypofractionated Radiotherapy for Post-Surgery Breast Cancer | ClinicalTrials.gov |
| NCT number | NCT07928427 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Phase 3 | ClinicalTrials.gov |
| Enrollment | 2,872 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Fudan University | ClinicalTrials.gov |
| Conditions | Breast Cancer, Radiotherapy | ClinicalTrials.gov |
| Interventions | Ultrafractionated Radiotherapy, Moderately Hypofractionated Radiotherapy | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Local-Regional Recurrence (LRR) | 5 years | Time from randomization to the first event of ipsilateral breast, chest wall, supraclavicular, axillary, or internal mammary nodal recurrence. | ClinicalTrials.gov |
| Secondary | Acute and Late Toxicities | 5 years | Assessment of radiation-related toxicities, including shoulder joint dysfunction, upper limb edema, shoulder pain, acute radiation skin reaction, radiation esophagitis, cardiovascular events (myocardial infarction, heart failure, acute coronary syndrome, valvular disease), radiation pneumonitis and pulmonary fibrosis, hypothyroidism, and brachial plexus injury. | ClinicalTrials.gov |
| Secondary | Overall Survival (OS) | 5 years | Time from randomization to death from any cause. | ClinicalTrials.gov |
| Secondary | Disease-Free Survival (DFS) | 5 years | Time from randomization to the first event of local-regional recurrence, distant recurrence, death from any cause, contralateral breast cancer, or second primary cancer. | ClinicalTrials.gov |
| Secondary | Distant Metastasis-Free Survival (DMFS) | 5 years | Time from randomization to the first event of recurrence at any site other than local-regional. | ClinicalTrials.gov |
| Secondary | Breast Cancer-Specific Survival (BCSS) | 5 years | Time from randomization to death due to breast cancer. Deaths from causes other than breast cancer will be handled according to the prespecified statistical analysis plan. | ClinicalTrials.gov |
| Secondary | EORTC Quality of Life Questionnaire (EORTC-QLQ-C30; version 3) | 5 years | Assessment of treatment-related symptoms, health-related quality of life via the EORTC Quality of Life Questionnaire (EORTC-QLQ-C30; version 3) | ClinicalTrials.gov |
| Secondary | breast cancer module (QLQ-BR23) | 5 years | Assessment of treatment-related symptoms, health-related quality of life via questionnaire breast cancer module (QLQ-BR23) | ClinicalTrials.gov |
| Secondary | the Quick Disabilities of the Arm, Shoulder and Hand (q-DASH) questionnaire. | 5 years | Assessment of upper limb function via the Quick Disabilities of the Arm, Shoulder and Hand (q-DASH) questionnaire. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)